At Aspen Laboratorios, we are pleased to introduce Vaxtor® (Ivacaftor), now part of our Oncology Division.

Indicated for the treatment of cystic fibrosis, this new therapy broadens the options available for patients facing this rare and complex condition.

Available presentation:

  • Coated tablets of 150 mg.

With Vaxtor®, we renew our commitment to providing healthcare professionals and patients with innovative solutions that improve quality of life in diseases requiring specialized care.